Hydroxyurea vs placebo
Adverse events or toxicity: differences in rates of specific adverse events · people with sickle cell disease
1 finding from 1 review
- no estimate extracted5 studies · 784 participantsLow
Findings
What do systematic reviews say?
4,703 questions · 15,007 findings · 1,416 reviews
No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Inhaled corticosteroids vs placebo
Combined outcome of mortality or BPD at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes combined outcome of mortality or BPD at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
- Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants 2022 · Cochrane Headline outcomes onlyRR 1.1 [0.74, 1.63]1 study · 30 participantsVery low
Inhaled corticosteroids vs placebo
Mortality at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes mortality at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
- Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants 2022 · Cochrane Headline outcomes onlyRR 3 [0.35, 25.78]3 studies · 61 participantsVery low
Inhaled corticosteroids vs placebo
Bronchopulmonary dysplasia/chronic lung disease · preterm infants
It is very uncertain whether inhaled corticosteroids changes BPD at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
- Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants 2022 · Cochrane Headline outcomes onlyRR 1 [0.59, 1.7]1 study · 30 participantsVery low
Inhaled corticosteroids vs placebo
Open‐label use of systemic corticosteroids · preterm infants
It is very uncertain whether inhaled corticosteroids changes open‐label use of systemic corticosteroids compared with placebo (very low certainty).
1 finding from 1 review
- Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants 2022 · Cochrane Headline outcomes onlyRR 0.51 [0.26, 1]4 studies · 74 participantsVery low
Alpha‐blockers vs placebo
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Comparison 12: SNRIs vs placebo
Dropouts due to adverse events · adults (aged 18‐85)
It is very uncertain whether comparison 5: SNRIs changes treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (very low certainty).
1 finding from 1 review
- RR 0.98 [0.88, 1.1]2 studies · 687 participantsVery low
Comparison 13: SSRIs vs placebo
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
Comparison 6: SSRIs probably leads to lower treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.66 [0.59, 0.74]8 studies · 1078 participantsModerate
Comparison 13: SSRIs vs placebo
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 6: SSRIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.98 [0.96, 1]14 studies · 2399 participantsModerate
Comparison 7: TCAs vs placebo
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
Comparison 7: TCAs may leads to lower treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (low certainty).
1 finding from 1 review
- RR 0.6 [0.38, 0.96]1 study · 40 participantsLow
Comparison 7: TCAs vs placebo
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 7: TCAs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.92 [0.81, 1.05]3 studies · 141 participantsModerate
Alpha‐blockers vs placebo
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 1: Alpha‐blockers showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.99 [0.91, 1.08]1 study · 304 participantsModerate
Antipsychotics vs placebo
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
It is very uncertain whether comparison 2: Antipsychotics changes treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (very low certainty).
1 finding from 1 review
- RR 0.51 [0.16, 1.67]2 studies · 43 participantsVery low
Antipsychotics vs placebo
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 2: Antipsychotics showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
1 finding from 1 review
- RR 0.98 [0.92, 1.05]5 studies · 348 participantsLow
MAOIs vs placebo
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
MAOIs vs placebo
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 3: MAOIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
1 finding from 1 review
- RR 1.14 [0.9, 1.43]1 study · 37 participantsLow
Comparison 9: NaSSAs vs placebo
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
Comparison 4: NaSSAs may leads to lower treatment efficacy ‐ Treatment response, as measured by the Global… compared with placebo (low certainty).
1 finding from 1 review
- RR 0.45 [0.22, 0.94]1 study · 26 participantsLow
Comparison 9: NaSSAs vs placebo
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 4: NaSSAs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
1 finding from 1 review
- RR 0.87 [0.68, 1.11]1 study · 36 participantsLow
Comparison 12: SNRIs vs placebo
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Aspirin vs placebo
Total mortality · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin showed no clear difference in total mortality compared with placebo (low certainty).
1 finding from 1 review
- OR 0.97 [0.87, 1.08]3 studies · 35794 participantsLow